Guggenheim Capital’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-56,801
| Closed | -$2.29M | – | 1709 |
|
|
2026
Q1 | $2.29M | Buy |
56,801
+20,154
| +55% | +$434K | 0.02% | 659 |
|
|
2025
Q4 | $921K | Buy |
36,647
+2,813
| +8% | +$66K | 0.01% | 989 |
|
|
2025
Q3 | $766K | Sell |
33,834
-4,619
| -12% | -$108K | 0.01% | 1013 |
|
|
2025
Q2 | $666K | Buy |
38,453
+3,105
| +9% | +$57.5K | 0.01% | 1044 |
|
|
2025
Q1 | $773K | Buy |
35,348
+2,741
| +8% | +$75.7K | 0.01% | 992 |
|
|
2024
Q4 | $1.04M | Sell |
32,607
-5,322
| -14% | -$160K | 0.01% | 900 |
|
|
2024
Q3 | $1.09M | Buy |
37,929
+4,316
| +13% | +$160K | 0.01% | 1051 |
|
|
2024
Q2 | $1.29M | Buy |
33,613
+111
| +0.3% | +$5.03K | 0.01% | 991 |
|
|
2024
Q1 | $1.97M | Buy |
33,502
+1,932
| +6% | +$123K | 0.01% | 886 |
|
|
2023
Q4 | $1.89M | Sell |
31,570
-9,535
| -23% | -$484K | 0.01% | 868 |
|
|
2023
Q3 | $1.56M | Buy |
41,105
+9,645
| +31% | +$424K | 0.01% | 898 |
|
|
2023
Q2 | $2.87M | Sell |
31,460
-4,532
| -13% | -$391K | 0.02% | 717 |
|
|
2023
Q1 | $2.37M | Sell |
35,992
-12,815
| -26% | -$739K | 0.02% | 787 |
|
|
2022
Q4 | $2.52M | Buy |
48,807
+13,288
| +37% | +$705K | 0.02% | 771 |
|
|
2022
Q3 | $2.43M | Sell |
35,519
-6,159
| -15% | -$364K | 0.02% | 766 |
|
|
2022
Q2 | $1.88M | Sell |
41,678
-1,421
| -3% | -$64.8K | 0.01% | 913 |
|
|
2022
Q1 | $2.19M | Sell |
43,099
-5,152
| -11% | -$227K | 0.01% | 962 |
|
|
2021
Q4 | $2.28M | Buy |
48,251
+4,607
| +11% | +$181K | 0.01% | 992 |
|
|
2021
Q3 | $1.44M | Buy |
+43,644
| New | +$2.45M | 0.01% | 1224 |
|
Other funds holding APLS
Guggenheim Capital's APLS Position: Q2 2026 in Review
Guggenheim Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 56,801 shares — an estimated $2.29M sold.
Guggenheim Capital first reported a position in APLS in Q3 2021 and held it in 19 quarters. The position peaked at $2.87M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Guggenheim Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Guggenheim Capital sold 56,801 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.29M.
- Guggenheim Capital first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 19 quarters.
- Guggenheim Capital's Apellis Pharmaceuticals position peaked at $2.87M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.